Department of Pathology, Siirt Research and Training Hospital, Siirt, Turkey.
Department of Pathology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Bosn J Basic Med Sci. 2022 Oct 23;22(6):894-900. doi: 10.17305/bjbms.2022.7574.
This study aimed to investigate the programmed cell death-ligand 1 (PD-L1) expression in cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) and its relationship with prognostic factors in tumors that are not in the head and neck region and are therefore relatively less exposed to the sun. This retrospective cross-sectional study included 25 invasive cSCC and 42 BCC cases with a diameter ≥ 2 cm located outside the head and neck region from 2010 to 2018. The biopsy samples were examined based on the membranous PD-L1 (22C3 clone) staining. Staining results were scored as follows: 0, no staining (negative); 1, < 10% PD-L1 positivity of tumor cells; and 2, ≥ 10% PD-L1 positivity of tumor cells. PD-L1 positivity was not seen in any BCC cases, whereas 11 (44%) of cSCC cases were PD-L1 positive. No significant relationship was observed between PD-L1 expression and prognostic parameters, including tumor diameter, tumor depth, and lymphovascular or perineural invasion in the cSCC group. PD-L1 expression was not associated with prognostic factors in the early stages of BCC and SCC located outside the head and neck region. Therefore, investigating the PD-L1 expression seems to be more relevant in patients with advanced-stage disease.
本研究旨在探讨非头颈部区域、受阳光照射相对较少的皮肤鳞状细胞癌（cSCC）和基底细胞癌（BCC）中程序性死亡配体 1（PD-L1）的表达及其与肿瘤预后因素的关系。本回顾性横断面研究纳入了 2010 年至 2018 年间 25 例侵袭性 cSCC 和 42 例直径≥2cm 的非头颈部区域 BCC 病例。采用膜 PD-L1（22C3 克隆）染色对活检样本进行检查。染色结果评分如下：0 分，无染色（阴性）；1 分，肿瘤细胞 PD-L1 阳性率<10%；2 分，肿瘤细胞 PD-L1 阳性率≥10%。在任何 BCC 病例中均未观察到 PD-L1 阳性，而 11 例（44%）cSCC 病例为 PD-L1 阳性。在 cSCC 组中，PD-L1 表达与肿瘤直径、肿瘤深度、血管淋巴管或神经周围侵犯等预后参数之间无显著关系。PD-L1 表达与非头颈部区域早期 BCC 和 SCC 的预后因素无关。因此，在晚期疾病患者中，检测 PD-L1 表达似乎更为相关。
